+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bimatoprost"

From
Ocular Hypertension - Pipeline Insight, 2025 - Product Thumbnail Image

Ocular Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Glaucoma Treatment Market - Forecasts from 2023 to 2028 - Product Thumbnail Image

Glaucoma Treatment Market - Forecasts from 2023 to 2028

  • Report
  • December 2023
  • 140 Pages
  • Global
From
Glaucoma - Competitive Landscape, 2023 - Product Thumbnail Image

Glaucoma - Competitive Landscape, 2023

  • Report
  • April 2023
  • 180 Pages
  • Global
From
Glaucoma Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Glaucoma Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • February 2024
  • 360 Pages
  • Global
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes. Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects. Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more